Search results for : jak2 - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Search Results for: jak2

Drugs (9)

Name	Synonyms	Targets	Target Pathway	PubCHEM	Datatset	Sample size	Screening site
AZ960	AZ 960, AZ-960	JAK2, JAK3	Other, kinases	25099184	GDSC2	892	SANGER
AZD1480	SN1044232195	JAK1, JAK2	Other, kinases		GDSC1	921	SANGER
Fedratinib	TG101348, TG-101348, SAR302503, SAR-302503	JAK2	Other, kinases	16722836	GDSC1	914	MGH
GSK2276186C		JAK1, JAK2, JAK3	Other, kinases		GDSC2	717	SANGER
JAK_8517	SN1066590414, JAK_8517	JAK1, JAK2	Other, kinases		GDSC2	717	SANGER
Lestaurtinib	CEP-701, SP-924, SPM-924, A-154475, KT-555	FLT3, JAK2, NTRK1, NTRK2, NTRK3	Other, kinases	126565	GDSC1	929	SANGER
Lestaurtinib	CEP-701, SP-924, SPM-924, A-154475, KT-555	FLT3, JAK2, NTRK1, NTRK2, NTRK3	Other, kinases	126565	GDSC2	947	SANGER
Ruxolitinib	INCB-18424, Ruxolitinib Phosphate, Jakafi	JAK1, JAK2	Other, kinases	25126798	GDSC1	916	MGH
Ruxolitinib	INCB-18424, Ruxolitinib Phosphate, Jakafi	JAK1, JAK2	Other, kinases	25126798	GDSC2	898	SANGER

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).